Search
Results
showing 1-10 of 5571
HIV Vaccine Clinical Trials Pipeline
This graphic summarizes the state of HIV vaccine research, detailing the different immunological approaches in clinical trials, the specific candidates being studied, and the collaborative networks of funders and developers working toward an effective vaccine.
Global Health Watch: 4 African Countries Sign Bilateral Health MoUs with US, New People’s Research Agenda, Hepatitis B Vaccine Shift
This week covers fast-moving developments with new US bilateral Memos of Understanding (MoU) across Africa, including reactions from Kenya’s High Court, which suspended the agreement over the issue of sharing of health data, alongside new reporting on the adverse impact of US policy changes affecting science and research institutions, and a major reversal in US hepatitis B vaccine policy. We also track the newly updated People’s Research Agenda.
PrEP Price Comparison
Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir.
Track the Science; Advance the Priorities
The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.
An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible
The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.
showing 1-10 of 5571